We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Four-in-One Test Kit for Detecting Influenza A, Influenza B, RSV and SARS-CoV-2 Set to Launch in November

By LabMedica International staff writers
Posted on 24 Sep 2020
A new four-in-one test kit for detecting influenza A, influenza B, RSV and SARS-CoV-2 is set to be launched in the coming month of November before the flu season begins in the Northern hemisphere.

Abacus Diagnostica (Turku, Finland) is developing the four-in-one test kit and plans to seek CE IVD approval for the multiplexed assay detecting influenzas, RSV and SARS-CoV-2. More...
Since the beginning of COVID-19 outbreak, the company has been developing SARS-CoV-2 diagnostics. In July 2020, its SARS-CoV-2 assay for the GenomEra CDX system received the CE IVD approval for the European market.

GenomEra SARS-CoV-2 is a rapid multiplex RT-PCR test for the detection of RdRp and E genes. RNA extraction is not needed, which dramatically reduces the time and workload of the laboratory personnel. Results are automatically and reliably reported by GenomEra software.The sample preparation is simple and requiring only one quick heating step. GenomEra Test Chips contain all the reagents needed for RT-PCR, which enables performing the testing in laboratories without any earlier experience of PCR. The results from the PCR-based COVID-19 test are available within 75 minutes. Because of the ease and rapidity of the system, many hospitals are using the assay for urgent samples such as testing hospital personnel.

In addition to the COVID-19 assay, the company has been working on a four-in-one test kit for detecting influenza A, influenza B, RSV and SARS-CoV-2. In the Northern hemisphere, the flu season is approaching now on top of the COVID-19 pandemic. The company plans to seek the CE IVD approval for the multiplexed assay detecting influenzas, RSV and SARS-CoV-2. The time frame is set by the approaching flu season. Abacus is aiming for the market launch with well available, CE IVD approved four-in-one assay in November, in a good time before the flu season begins.

“The COVID-19 testing is essential to manage and control the pandemic. When everyone is focused on COVID-19, there is a risk of delays on the diagnosis and treatment of other infections,” said Mr. Erno Sundberg, the CEO of Abacus Diagnostica. “It would benefit the patients and save the resources of the health care system to test more than one pathogen at a time. The flu season awaits in the shade of COVID-19 outbreak, and our new assay will help to bring it on sight as soon as it sets off.”

Related Links:
Abacus Diagnostica


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Collection and Transport System
PurSafe Plus®
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.